Related references
Note: Only part of the references are listed.Significance of Liquid Biopsy for Monitoring and Therapy Decision of Colorectal Cancer
Susanne Klein-Scory et al.
TRANSLATIONAL ONCOLOGY (2018)
From tumour heterogeneity to advances in precision treatment of colorectal cancer
Cornelis J. A. Punt et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Chemotherapy delivery for resected colorectal cancer liver metastases: Management and outcomes in routine clinical practice
A. Krishnamurthy et al.
EJSO (2017)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases
Inger Marie Loes et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial
N. Normanno et al.
ANNALS OF ONCOLOGY (2015)
Hotspot Mutation Panel Testing Reveals Clonal Evolution in a Study of 265 Paired Primary and Metastatic Tumors
Rashmi S. Goswami et al.
CLINICAL CANCER RESEARCH (2015)
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Giulia Siravegna et al.
NATURE MEDICINE (2015)
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
Marco Gerlinger et al.
NATURE GENETICS (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial
Bernard Nordlinger et al.
LANCET ONCOLOGY (2013)
Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement
Roderich E. Schwarz et al.
HPB (2013)
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
D. Santini et al.
ANNALS OF ONCOLOGY (2012)
Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
Leonie J. M. Mekenkamp et al.
BMC CANCER (2012)
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Sandra Misale et al.
NATURE (2012)
Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer
Francesca Molinari et al.
CLINICAL CANCER RESEARCH (2011)
Share Paper
